Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen followed by HBV-targeted immunotherapy in chronic hepatitis B on nucleos(t)ide analogues
2024-512352-38-00Phase 2Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, single-blind trial of bepirovirsen and GSK3528869A in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoints: Grade 3 adverse events, Serious adverse events and 3 more. Started May 2024; status: completed.
02
Drugs
bepirovirsenGSK3528869A
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-512352-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512352-38-00.